Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators
Lancet Oncol 2024 May;25(5):572-587. Epub 2024 Mar 29 doi: 10.1016/S1470-2045(24)00100-1. PMID: 38561010

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.

Yan XQ, Ye MJ, Zou Q, Chen P, He ZS, Wu B, He DL, He CH, Xue XY, Ji ZG, Chen H, Zhang S, Liu YP, Zhang XD, Fu C, Xu DF, Qiu MX, Lv JJ, Huang J, Ren XB, Cheng Y, Qin WJ, Zhang X, Zhou FJ, Ma LL, Guo JM, Ding DG, Wei SZ, He Y, Guo HQ, Shi BK, Liu L, Liu F, Hu ZQ, Jin XM, Yang L, Zhu SX, Liu JH, Huang YH, Xu T, Liu B, Sun T, Wang ZJ, Jiang HW, Yu DX, Zhou AP, Jiang J, Luan GD, Jin CL, Xu J, Hu JX, Huang YR, Guo J, Zhai W, Sheng XN
Ann Oncol 2024 Feb;35(2):190-199. Epub 2023 Oct 21 doi: 10.1016/j.annonc.2023.09.3108. PMID: 37872020

Combined use of pembrolizumab and lenvatinib: A review.

Eisinger C, Muluneh B
J Oncol Pharm Pract 2023 Sep;29(6):1461-1466. Epub 2023 May 25 doi: 10.1177/10781552231178461. PMID: 37231712 Free PMC Article

Everolimus.

Hasskarl J
Recent Results Cancer Res 2018;211:101-123. doi: 10.1007/978-3-319-91442-8_8. PMID: 30069763

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J
Lancet Oncol 2017 Nov;18(11):1483-1492. Epub 2017 Sep 26 doi: 10.1016/S1470-2045(17)30616-2. PMID: 28967485

See all (129)

Diagnosis

Local and distant recurrence of the chromophobe renal cell carcinoma.

Armas-Alvarez AL, Alois Osorio-Manyari A, Donate-Moreno MJ, Vera-Beron R, Salinas-Sánchez AS
Arch Esp Urol 2020 Jan;73(1):71-75. PMID: 31950927

Treatment of advanced pediatric renal cell carcinoma.

Ambalavanan M, Geller JI
Pediatr Blood Cancer 2019 Aug;66(8):e27766. Epub 2019 Apr 23 doi: 10.1002/pbc.27766. PMID: 31012542

Acrometastases.

Mavrogenis AF, Mimidis G, Kokkalis ZT, Karampi ES, Karampela I, Papagelopoulos PJ, Armaganidis A
Eur J Orthop Surg Traumatol 2014 Apr;24(3):279-83. Epub 2013 Sep 8 doi: 10.1007/s00590-013-1311-1. PMID: 24013815

Renal cell carcinoma in children and adolescents.

Spreafico F, Collini P, Terenziani M, Marchianò A, Piva L
Expert Rev Anticancer Ther 2010 Dec;10(12):1967-78. doi: 10.1586/era.10.188. PMID: 21110762

See all (56)

Therapy

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Sunitinib.

Heng DY, Kollmannsberger C
Recent Results Cancer Res 2010;184:71-82. doi: 10.1007/978-3-642-01222-8_6. PMID: 20072832

Sunitinib.

Deeks ED, Keating GM
Drugs 2006;66(17):2255-66; discussion 2267-8. doi: 10.2165/00003495-200666170-00007. PMID: 17137406

See all (230)

Prognosis

Overexpression of kif11 is a poor prognostic factor in clear cell renal cell carcinoma.

Kowalewski A, Jaworski D, Antosik P, Smolińska M, Ligmanowska J, Grzanka D, Szylberg Ł
Pol J Pathol 2022;73(2):82-87. doi: 10.5114/pjp.2022.118137. PMID: 35979754

Treatment of advanced pediatric renal cell carcinoma.

Ambalavanan M, Geller JI
Pediatr Blood Cancer 2019 Aug;66(8):e27766. Epub 2019 Apr 23 doi: 10.1002/pbc.27766. PMID: 31012542

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.

Tomita Y
Int J Urol 2016 Jan;23(1):13-21. Epub 2015 Sep 7 doi: 10.1111/iju.12899. PMID: 26347163

Acrometastases.

See all (101)

Clinical prediction guides

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.

Soares A, Monteiro FSM, da Trindade KM, Silva AGE, Cardoso APG, Sasse AD, Fay AP, Carneiro APCD, Alencar Junior AM, de Andrade Mota AC, Santucci B, da Motta Girardi D, Herchenhorn D, Araújo DV, Jardim DL, Bastos DA, Rosa DR, Schutz FA, Kater FR, da Silva Marinho F, Maluf FC, de Oliveira FNG, Vidigal F, Morbeck IAP, Rinck Júnior JA, Costa LAGA, Maia MCDF, Zereu M, Freitas MRP, Dias MSF, Tariki MS, Muniz P, Beato PMM, Lages PSM, Velho PI, de Carvalho RS, Mariano RC, de Araújo Cavallero SR, Oliveira TM, Souza VC, Smaletz O, de Cássio Zequi S
J Cancer Res Clin Oncol 2024 Apr 9;150(4):183. doi: 10.1007/s00432-024-05663-z. PMID: 38594593 Free PMC Article

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.

Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review.

Roy AM, Briggler A, Tippit D, Dawson K, Verma R
Clin Genitourin Cancer 2020 Dec;18(6):e688-e691. Epub 2020 Apr 21 doi: 10.1016/j.clgc.2020.04.003. PMID: 32660880

Nivolumab-induced Adrenal Insufficiency in Patients With Renal Cell Carcinoma.

Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M
J Immunother 2020 Jan;43(1):38-42. doi: 10.1097/CJI.0000000000000299. PMID: 31567704

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

See all (94)